# Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic Cancer

> **NCT05832892** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 41 (estimated)

## Conditions studied

- Unresectable Locally Advanced or Metastatic Pancreatic Cancer

## Interventions

- **DRUG:** surufatinib
- **DRUG:** KN046
- **DRUG:** gemcitabine
- **DRUG:** Nab paclitaxel

## Key facts

- **NCT ID:** NCT05832892
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-11-01
- **Primary completion:** 2024-11-01
- **Final completion:** 2025-06-01
- **Target enrollment:** 41 (ESTIMATED)
- **Last updated:** 2024-06-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05832892

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05832892, "Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05832892. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*